Piperacillin–tazobactam as alternative to carbapenems for ICU patients
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Piperacillin–tazobactam as alternative to carbapenems for ICU patients
Authors
Keywords
Carbapenems, ESBL, Alternatives, Ecological consequences, Outcome
Journal
Annals of Intensive Care
Volume 7, Issue 1, Pages -
Publisher
Springer Nature
Online
2017-11-10
DOI
10.1186/s13613-017-0334-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effect of a multifaceted educational intervention for anti-infectious measures on sepsis mortality: a cluster randomized trial
- (2017) Frank Bloos et al. INTENSIVE CARE MEDICINE
- Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016
- (2017) Andrew Rhodes et al. INTENSIVE CARE MEDICINE
- Piperacillin/tazobactam as an alternative antibiotic therapy to carbapenems in the treatment of urinary tract infections due to extended-spectrum β-lactamase-producing Enterobacteriaceae: an in silico pharmacokinetic study
- (2017) Hélène Guet-Revillet et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- The human microbiota: novel targets for hospital-acquired infections and antibiotic resistance
- (2016) Melinda M. Pettigrew et al. ANNALS OF EPIDEMIOLOGY
- Risk factors for fecal carriage of carbapenemase producing Enterobacteriaceae among intensive care unit patients from a tertiary care center in India
- (2016) Gajanand Mittal et al. BMC MICROBIOLOGY
- Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation β-Lactam/β-Lactamase Inhibitor Combinations
- (2016) David van Duin et al. CLINICAL INFECTIOUS DISEASES
- Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society
- (2016) Andre C. Kalil et al. CLINICAL INFECTIOUS DISEASES
- Pharmacokinetics and Pharmacodynamics of Extended Infusion Versus Short Infusion Piperacillin-Tazobactam in Critically Ill Patients Undergoing CRRT
- (2016) M. S. Shotwell et al. Clinical Journal of the American Society of Nephrology
- Susceptibility patterns and ESBL rates of Escherichia coli from urinary tract infections in Canada and the United States, SMART 2010–2014
- (2016) Sibylle H. Lob et al. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
- Risk factors and clinical outcomes for carbapenem-resistant Enterobacteriaceae nosocomial infections
- (2016) Q. Wang et al. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
- Epidemiology and antimicrobial susceptibility profiles of pathogens causing urinary tract infections in the Asia-Pacific region: Results from the Study for Monitoring Antimicrobial Resistance Trends (SMART), 2010–2013
- (2016) Shio-Shin Jean et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Piperacillin population pharmacokinetics in critically ill patients with multiple organ dysfunction syndrome receiving continuous venovenous haemodiafiltration: effect of type of dialysis membrane on dosing requirements
- (2016) Marta Ulldemolins et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Colonization and infection with extended-spectrum β-lactamase-producing Enterobacteriaceae in ICU patients: what impact on outcomes and carbapenem exposure?
- (2016) François Barbier et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Efficacy of ceftolozane/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing Escherichia coli and Klebsiella pneumoniae : a pooled analysis of Phase 3 clinical trials
- (2016) Myra W. Popejoy et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Cefepime Therapy for Cefepime-Susceptible Extended-Spectrum β-Lactamase-ProducingEnterobacteriaceaeBacteremia: Table 1.
- (2016) Ruibin Wang et al. Open Forum Infectious Diseases
- Empiric Piperacillin-Tazobactam versus Carbapenems in the Treatment of Bacteraemia Due to Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae
- (2016) Tat Ming Ng et al. PLoS One
- Multicenter Retrospective Study of Cefmetazole and Flomoxef for Treatment of Extended-Spectrum-β-Lactamase-Producing Escherichia coli Bacteremia
- (2015) Yasufumi Matsumura et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- A Systematic Review of the Definitions, Determinants, and Clinical Outcomes of Antimicrobial De-escalation in the Intensive Care Unit
- (2015) Alexis Tabah et al. CLINICAL INFECTIOUS DISEASES
- Carbapenems Versus Piperacillin-Tazobactam for Bloodstream Infections of Nonurinary Source Caused by Extended-Spectrum Beta-Lactamase–Producing Enterobacteriaceae
- (2015) Hadas Ofer-Friedman et al. INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY
- Forecasting carbapenem resistance from antimicrobial consumption surveillance: Lessons learnt from an OXA-48-producing Klebsiella pneumoniae outbreak in a West London renal unit
- (2015) M. Gharbi et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient outcomes? An observation from the Defining Antibiotic Levels in Intensive care unit patients (DALI) cohort
- (2015) Mohd H. Abdul-Aziz et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Risk factors of community-onset urinary tract infections caused by plasmid-mediated AmpC β-lactamase-producing Enterobacteriaceae
- (2015) Chi-Hung Lee et al. JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION
- β-lactam and β-lactamase inhibitor combinations in the treatment of extended-spectrum β-lactamase producing Enterobacteriaceae: time for a reappraisal in the era of few antibiotic options?
- (2015) Patrick N A Harris et al. LANCET INFECTIOUS DISEASES
- Risk factors for carbapenem-resistantKlebsiella pneumoniaeinfection/colonization and predictors of mortality: a retrospective study
- (2015) Yang Jiao et al. Pathogens and Global Health
- Risk factors for acquisition of carbapenem resistant Enterobacteriaceae in an acute tertiary care hospital in Singapore
- (2015) Moi Lin Ling et al. Antimicrobial Resistance and Infection Control
- Comparable outcomes for β-lactam/β-lactamase inhibitor combinations and carbapenems in definitive treatment of bloodstream infections caused by cefotaxime-resistant Escherichia coli or Klebsiella pneumoniae
- (2015) Patrick N A Harris et al. Antimicrobial Resistance and Infection Control
- Risk factors for colonization with carbapenemase-producing Klebsiella pneumoniae in hospital: A matched case-control study
- (2014) Carlo Gagliotti et al. AMERICAN JOURNAL OF INFECTION CONTROL
- Risk factors for the acquisition of carbapenem-resistant Escherichia coli at a tertiary care center in South Korea: A matched case-control study
- (2014) Jin Young Ahn et al. AMERICAN JOURNAL OF INFECTION CONTROL
- Individualization of Piperacillin Dosing for Critically Ill Patients: Dosing Software To Optimize Antimicrobial Therapy
- (2014) T. W. Felton et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Pharmacological Study of Cefoxitin as an Alternative Antibiotic Therapy to Carbapenems in Treatment of Urinary Tract Infections Due to Extended-Spectrum-β-Lactamase-Producing Escherichia coli
- (2014) H. Guet-Revillet et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In VitroSusceptibility of Characterized β-Lactamase-Producing Strains Tested with Avibactam Combinations
- (2014) Henry Li et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Pulmonary Penetration of Piperacillin and Tazobactam in Critically Ill Patients
- (2014) T W Felton et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Carbapenems and piperacillin/tazobactam for the treatment of bacteremia caused by extended-spectrum β-lactamase–producing Proteus mirabilis
- (2014) Hsih-Yeh Tsai et al. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
- Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalised with pneumonia in US and European hospitals: Results from the SENTRY Antimicrobial Surveillance Program, 2009–2012
- (2014) Helio S. Sader et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Temocillin (6 g daily) in critically ill patients: continuous infusion versus three times daily administration
- (2014) P.-F. Laterre et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions
- (2014) Jason A Roberts et al. LANCET INFECTIOUS DISEASES
- Risk factors for infection and predictors of mortality among patients with KPC-producing Klebsiella pneumoniae bloodstream infections in the intensive care unit
- (2014) Matthaios Papadimitriou-Olivgeris et al. SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES
- Emergence of carbapenem-resistant Klebsiella spp. infections in a Turkish university hospital: epidemiology and risk factors
- (2014) Murat Dizbay et al. Journal of Infection in Developing Countries
- Impact of the MIC of Piperacillin-Tazobactam on the Outcome of Patients with Bacteremia Due to Extended-Spectrum-β-Lactamase-Producing Escherichia coli
- (2013) Pilar Retamar et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Impact of Antibiotic Use on Carbapenem Resistance in Pseudomonas aeruginosa: Is There a Role for Antibiotic Diversity?
- (2013) C. Plüss-Suard et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Emergence of Imipenem-Resistant Gram-Negative Bacilli in Intestinal Flora of Intensive Care Patients
- (2013) Laurence Armand-Lefèvre et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Therapeutic drug monitoring-based dose optimisation of piperacillin and meropenem: a randomised controlled trial
- (2013) Jan J. De Waele et al. INTENSIVE CARE MEDICINE
- Population pharmacokinetics and dosing simulations of amoxicillin/clavulanic acid in critically ill patients
- (2013) M. Carlier et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Pharmacokinetic Analysis of Piperacillin Administered with Tazobactam in Critically Ill, Morbidly Obese Surgical Patients
- (2013) Ashley W. Sturm et al. PHARMACOTHERAPY
- Risk Factors for the First Episode of Klebsiella pneumoniae Resistant to Carbapenems Infection in Critically Ill Patients: A Prospective Study
- (2013) Konstantinos Mantzarlis et al. Biomed Research International
- Vancomycin-resistant Enterococcus carrier status in the reanimation units and related risk factors
- (2012) Nur Efe Iris et al. AMERICAN JOURNAL OF INFECTION CONTROL
- Risk associated with a systematic search of extended-spectrum β-lactamase–producing Enterobacteriaceae
- (2012) Roberta Prinapori et al. AMERICAN JOURNAL OF INFECTION CONTROL
- Impact of Cefepime Therapy on Mortality among Patients with Bloodstream Infections Caused by Extended-Spectrum-β-Lactamase-Producing Klebsiella pneumoniae and Escherichia coli
- (2012) Teena Chopra et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Cefepime Therapy for Monomicrobial Bacteremia Caused by Cefepime-Susceptible Extended-Spectrum Beta-Lactamase–Producing Enterobacteriaceae: MIC Matters
- (2012) Nan-Yao Lee et al. CLINICAL INFECTIOUS DISEASES
- Continuous Infusion of Beta-Lactam Antibiotics in Severe Sepsis: A Multicenter Double-Blind, Randomized Controlled Trial
- (2012) J. M. Dulhunty et al. CLINICAL INFECTIOUS DISEASES
- Patient risk factors for outer membrane permeability and KPC-producing carbapenem-resistant Klebsiella pneumoniae isolation: results of a double case–control study
- (2012) G. B. Orsi et al. INFECTION
- Risk factors for KPC-producing Klebsiella pneumoniae enteric colonization upon ICU admission
- (2012) M. Papadimitriou-Olivgeris et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Piperacillin–tazobactam as an initial empirical therapy of bacteremia caused by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae
- (2012) Cheol-In Kang et al. JOURNAL OF INFECTION
- Effect of Antibiotic Treatment on Establishment and Elimination of Intestinal Colonization by KPC-Producing Klebsiella pneumoniae in Mice
- (2011) Federico Perez et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Bacteremia Caused by Extended-Spectrum-β-Lactamase-Producing Escherichia coli Sequence Type ST131 and Non-ST131 Clones: Comparison of Demographic Data, Clinical Features, and Mortality
- (2011) Hsing-Chun Chung et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- -Lactam/ -Lactam Inhibitor Combinations for the Treatment of Bacteremia Due to Extended-Spectrum -Lactamase-Producing Escherichia coli: A Post Hoc Analysis of Prospective Cohorts
- (2011) J. Rodriguez-Bano et al. CLINICAL INFECTIOUS DISEASES
- The effect of inappropriate therapy on bacteremia by ESBL-producing bacteria
- (2011) F. G. De Rosa et al. INFECTION
- Extended-spectrum β-lactamase-producing Gram-negative pathogens in community-acquired urinary tract infections: an increasing challenge for antimicrobial therapy
- (2011) S. Meier et al. INFECTION
- Temocillin use in England: clinical and microbiological efficacies in infections caused by extended-spectrum and/or derepressed AmpC β-lactamase-producing Enterobacteriaceae
- (2011) Indran Balakrishnan et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Risk factors and outcomes of carbapenem-nonsusceptible Escherichia coli bacteremia: A matched case–control study
- (2011) Hong-Jyun Chang et al. JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION
- Factores de riesgo de mortalidad en pacientes con bacteriemia por cepas productoras de betalactamasas de espectro extendido
- (2011) O. Ferrández et al. REVISTA CLINICA ESPANOLA
- Therapeutic Drug Monitoring of Piperacillin-Tazobactam Using Spent Dialysate Effluent in Patients Receiving Continuous Venovenous Hemodialysis
- (2010) Michael J. Connor et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Bacteremia Due to Extended-Spectrum- -Lactamase-Producing Enterobacter cloacae: Role of Carbapenem Therapy
- (2010) C.-C. Lee et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Three Decades of -Lactamase Inhibitors
- (2010) S. M. Drawz et al. CLINICAL MICROBIOLOGY REVIEWS
- Therapeutic drug monitoring of β-lactams in critically ill patients: proof of concept
- (2010) Jason A. Roberts et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Risk factors and outcome of extended-spectrum β-lactamase-producing Enterobacter cloacae bloodstream infections
- (2010) Zubair A. Qureshi et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Epidemiology of extended spectrum β-lactamase producing Enterobacter bacteremia in a brazilian hospital
- (2010) Felipe Francisco Tuon et al. Revista da Sociedade Brasileira de Medicina Tropical
- Piperacillin penetration into tissue of critically ill patients with sepsis—Bolus versus continuous administration?
- (2009) Jason A. Roberts et al. CRITICAL CARE MEDICINE
- Risk Factors and Clinical Impact of Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae
- (2009) Leanne B. Gasink et al. INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY
- Bacteraemia due to extended-spectrum -lactamase-producing Escherichia coli (ESBL-EC) in cancer patients: clinical features, risk factors, molecular epidemiology and outcome
- (2009) C. Gudiol et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Nationwide survey of extended-spectrum β-lactamase-producing Enterobacteriaceae in the French community setting
- (2009) C. Arpin et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution
- (2009) Jason A. Roberts et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Predictors of Mortality From Community-Onset Bloodstream Infections Due to Extended-Spectrum β-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae
- (2008) Anucha Apisarnthanarak et al. INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY
- Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections
- (2008) Peggy S. McKinnon et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started